Merck's HIV combo treatment approved by FDA

• The combination therapy pairs Merck's already-approved doravirine (marketed as Pifeltro and Delstrigo) with the experimental treatment islatravir
• The regimen is approved to replace existing antiretroviral treatments for HIV-1 infection in certain adult patients
• Globally, 40.8 million people live with HIV and roughly 1.3 million new infections occur each year, according to NIH data

Summary

Key Development:

The U.S. Food and Drug Administration approved Merck's once-daily oral combination treatment for HIV-1 infections on April 21. The two-drug regimen combines doravirine and islatravir, designed to replace current antiretroviral therapies in certain adult patients.

Product Details:

• Doravirine is already FDA-approved and marketed under brand names Pifeltro (used with other antiretrovirals) and Delstrigo (single-tablet regimen)
• Islatravir remains an experimental treatment, making this approval significant for expanding its clinical use
• The combination offers a simplified once-daily oral dosing regimen

Market Context:

According to National Institutes of Health data, approximately 40.8 million people worldwide are living with HIV, with 1.3 million new infections occurring annually. This substantial patient population represents a significant market opportunity for Merck's newly approved treatment.

Company Response:

Merck did not immediately provide comment on the approval.

Implications:

This approval strengthens Merck's position in the competitive HIV treatment market by offering healthcare providers and patients an additional therapeutic option. The combination therapy approach may improve treatment adherence and outcomes compared to more complex multi-drug regimens. The approval of islatravir in combination form could pave the way for additional applications of the experimental drug. For investors, this represents potential revenue growth in Merck's infectious disease portfolio, particularly given the large global HIV patient population requiring ongoing treatment management.